

AMENDED VERSION

IN THE SPECIFICATION:

Page 1, after the Title, please insert the following section:

CROSS REFERENCE TO RELATED APPLICATIONS

A
This patent application is a National Phase Concerning a Filing Under 35 U.S.C 371, claiming the benefit of priority of PCT/IL00/00312, filed May 31, 2000, which claims the benefit of priority of Israeli Serial Number 130255, filed May 31, 1999, all of which are incorporated herein by reference.

IN THE CLAIMS:

A²
6. (Amended) A method for the diagnosis of one of central nervous system (CNS) stress and disruption of the blood-brain-barrier in a mammal, comprising obtaining a sample from said mammal, contacting said sample with an antibody of claim 1, removing unbound antibody, and detecting the extent of reaction between said antibody and acetylcholinesterase or a fragment thereof present in said sample.

7. (Amended) A method for the diagnosis of one central nervous system (CNS) stress and disruption of the blood-brain-barrier in a mammal, comprising contacting a sample of said mammal with an antibody of claim 1, removing unbound antibody, and detecting the extent of reaction between said antibody and acetylcholinesterase or a fragment thereof present in said sample.

8. (Amended) The method of claim 6, wherein the CNS stress is caused by one of physical, chemical and psychological insult.

A²
11. (Amended) A method for the diagnosis of Alzheimer's disease in a subject, comprising obtaining a sample from said subject, contacting said sample with an antibody of claim 1, removing unbound antibody, and detecting the extent of reaction

between said antibody and acetylcholinesterase or a fragment thereof present in said sample.

12. (Amended) A method for the diagnosis of Alzheimer's disease in a subject, comprising contacting a sample of said mammal with an antibody of claim 1, removing unbound antibody, and detecting the extent of reaction between said antibody and acetylcholinesterase or a fragment thereof present in said sample.

A2
(CNS)
13. (Amended) A method according to claim 6, wherein the sample is one of serum and cerebrospinal fluid sample.

14. (Amended) A method according to claim 11, wherein the sample is one of serum and cerebrospinal fluid sample.

15. (Amended) Use of the antibodies of claim 1, in the diagnosis of one of central nervous system (CNS) stress, Alzheimer's disease and disruption of the blood-brain-barrier in a mammal.
